

Precision Oncology Diagnostics Forum

15 April 2023, Saturday

📍 Online- Zoom Webinar

Presentations 1pm – 6pm (SGT +8)

Organizer

Singapore
Society of
Oncology



Organizing Partners

illumina®

AstraZeneca



**Click here or
scan QR code
to register**



Co-Chairpersons



Dr Tony Lim
Singapore General Hospital
Singapore



Dr Ravindran Kanesvaran
National Cancer Centre
Singapore

Speakers



Dr Paul Hofman
University Cote d'Azur
France



Prof Jae Young Joung
National Cancer Center
Korea



Prof Nick Pavlakis
University of Sydney
Australia



Dr Tan Min-Han
Lucence Health Inc
Singapore



Dr Adele Wong
KK Women's and Children's Hospital
Singapore

Objective of the meeting:

Advances in tumor genome sequencing have enabled discovery of actionable alterations leading to novel therapies. Currently, there are approved targeted therapies across various tumors that can be matched to genomic alterations. Tools to detect these genomic alterations have emerged as a result of decreasing costs and improved throughput enabled by next-generation sequencing (NGS) technologies. While multigene sequencing tests are starting to be used more commonly during a patient's care path, there has been debate about the overall clinical impact of comprehensive genomic profiling (CGP). There is also a lack of guidance for oncologists on how to interpret the results of genomic and ctDNA testing; specifically on how to apply them to therapeutic decision making hence clinical application of CGP presents some potential challenges in terms of tumor specimen acquisition, analysis, interpretation and privacy. In this educational meeting we aim to bring together national leading Clinicians and Pathologists on a common platform to -

1. Raise awareness on Comprehensive Genomic Profiling and its utility in management of cancer patients
2. Highlight the advantages of consolidated biomarker detection via a single multiplex assay, eliminating the need for sequential testing
3. Discuss current status, drivers and barriers for adoption of CGP in clinical practice
4. Highlight evolving landscape of cancer biomarkers such as HRD

Programme

Time (SGT) Topic

1.20PM	Opening Address and Introduction Dr Tony Lim
1.30PM	Challenges and opportunities for NGS testing in NSCLC Dr Paul Hofman
2.00PM	CGP in Lung Cancer and Experience with National-level Clinical Trials Prof Nick Pavlakis
2.30PM	CGP and Liquid biopsy in Lung and Prostate Cancer Dr Tan Min-Han
3.00PM	Tea Break
3.30PM	Optimizing HRR mut testing in Prostate Cancer Prof Jae Young Joung
4.00PM	CGP and HRD in Ovarian Cancer Dr Adele Wong
4.30PM	Panel Discussion All
5.50PM	Closing Dr Ravindran Kanesvaran